Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,702,528
  • Shares Outstanding, K 90,821
  • Annual Sales, $ 451,240 K
  • Annual Income, $ 21,110 K
  • 60-Month Beta 1.86
  • Price/Sales 16.99
  • Price/Cash Flow 168.33
  • Price/Book 15.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.91
  • Number of Estimates 9
  • High Estimate 0.09
  • Low Estimate -1.40
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -93.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.70 +14.61%
on 03/06/19
86.16 -0.64%
on 03/18/19
+4.72 (+5.84%)
since 02/19/19
3-Month
66.71 +28.33%
on 12/24/18
92.71 -7.66%
on 01/23/19
+13.63 (+18.94%)
since 12/19/18
52-Week
64.72 +32.28%
on 12/12/18
126.98 -32.58%
on 09/13/18
+0.48 (+0.56%)
since 03/19/18

Most Recent Stories

More News
CTLT or NBIX: Which Is the Better Value Stock Right Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT : 42.69 (+0.28%)
NBIX : 85.99 (+1.39%)
Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of...

NBIX : 85.99 (+1.39%)
Watch for Neurocrine Biosc to Potentially Pullback After Gaining 3.15% Yesterday

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $78.18 to a high of $79.98. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high...

NBIX : 85.99 (+1.39%)
Stocks Slide for Third Straight Day

Stocks Slide for Third Straight Day

ZBH : 125.68 (+0.29%)
STMP : 85.71 (-1.12%)
WUBA : 62.83 (+0.46%)
DBD : 11.08 (-2.64%)
NBIX : 85.99 (+1.39%)
RECN : 17.30 (+0.99%)
SmarTrend Watching for Potential Rebound in Shares of Neurocrine Biosc After 1.46% Loss

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $75.36 to a high of $76.69. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of...

NBIX : 85.99 (+1.39%)
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following...

NBIX : 85.99 (+1.39%)
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT : 42.69 (+0.28%)
NBIX : 85.99 (+1.39%)
Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 35.71% and -0.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 85.99 (+1.39%)
Neurocrine: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported fourth-quarter profit of $18.1 million.

NBIX : 85.99 (+1.39%)
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended December 31, 2018 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical...

NBIX : 85.99 (+1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NBIX with:

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 87.20
1st Resistance Point 86.01
Last Price 85.99
1st Support Level 83.77
2nd Support Level 82.72

See More

52-Week High 126.98
Fibonacci 61.8% 103.20
Fibonacci 50% 95.85
Fibonacci 38.2% 88.50
Last Price 85.99
52-Week Low 64.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar